OBJECTIVE: This study compares surgical and survival outcomes of women with stage IV uterine serous carcinoma (USC) treated with neoadjuvant chemotherapy (NAC) and interval cytoreduction to women treated with primary cytoreductive surgery (PCS) followed by adjuvant chemotherapy. METHODS: This retrospective dual cohort study included women diagnosed with stage IV USC at a single academic institution. Kruskal-Wallis and Fisher exact tests were used to compare demographics and surgical outcomes. Progression-free survival (PFS) and overall survival (OS) were estimated by using Kaplan-Meier methods. Comparison between study groups was tested by log-rank statistics. RESULTS: Ten women with stage IV USC who received NAC and 34 who underwent PCS met inclusion criteria. Neoadjuvant chemotherapy patients had a lower mean body mass index and were more often African American. Compared with PCS, the NAC cohort had shorter mean operative times (137 ± 66 vs 203 ± 80 minutes, P = 0.025) and were discharged from the hospital earlier (median length of stay, 3 vs 5 days; P = 0.002). Rates of debulking to no gross residual disease (70% NAC vs 32.3% PCS) or less than 1 cm of disease (30% NAC vs 50% PCS) did not differ (P = 0.10). Median follow-up time was 17.5 months. There was no difference in median PFS (10.4 vs 12 months, P = 0.29) or OS (17.3 vs 20.7 months, P = 0.23) for NAC and PCS cohorts. CONCLUSIONS: Women receiving NAC for stage IV USC had shorter surgeries and hospital stays than did those receiving PCS. There was no difference in PFS or OS, although our sample size was small. Neoadjuvant chemotherapy may be an appropriate therapy for select patients with advanced-stage USC.
OBJECTIVE: This study compares surgical and survival outcomes of women with stage IV uterine serous carcinoma (USC) treated with neoadjuvant chemotherapy (NAC) and interval cytoreduction to women treated with primary cytoreductive surgery (PCS) followed by adjuvant chemotherapy. METHODS: This retrospective dual cohort study included women diagnosed with stage IV USC at a single academic institution. Kruskal-Wallis and Fisher exact tests were used to compare demographics and surgical outcomes. Progression-free survival (PFS) and overall survival (OS) were estimated by using Kaplan-Meier methods. Comparison between study groups was tested by log-rank statistics. RESULTS: Ten women with stage IV USC who received NAC and 34 who underwent PCS met inclusion criteria. Neoadjuvant chemotherapy patients had a lower mean body mass index and were more often African American. Compared with PCS, the NAC cohort had shorter mean operative times (137 ± 66 vs 203 ± 80 minutes, P = 0.025) and were discharged from the hospital earlier (median length of stay, 3 vs 5 days; P = 0.002). Rates of debulking to no gross residual disease (70% NAC vs 32.3% PCS) or less than 1 cm of disease (30% NAC vs 50% PCS) did not differ (P = 0.10). Median follow-up time was 17.5 months. There was no difference in median PFS (10.4 vs 12 months, P = 0.29) or OS (17.3 vs 20.7 months, P = 0.23) for NAC and PCS cohorts. CONCLUSIONS:Women receiving NAC for stage IV USC had shorter surgeries and hospital stays than did those receiving PCS. There was no difference in PFS or OS, although our sample size was small. Neoadjuvant chemotherapy may be an appropriate therapy for select patients with advanced-stage USC.
Authors: J Alejandro Rauh-Hain; Whitfield B Growdon; John O Schorge; A K Goodman; David M Boruta; Christopher McCann; Neil S Horowitz; Marcela G del Carmen Journal: Gynecol Oncol Date: 2010-08-05 Impact factor: 5.482
Authors: F D Cirisano; S J Robboy; R K Dodge; R C Bentley; H R Krigman; I S Synan; J T Soper; D L Clarke-Pearson Journal: Gynecol Oncol Date: 2000-04 Impact factor: 5.482
Authors: Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: Thomas Hogberg; Mauro Signorelli; Carlos Freire de Oliveira; Roldano Fossati; Andrea Alberto Lissoni; Bengt Sorbe; Håkan Andersson; Seija Grenman; Caroline Lundgren; Per Rosenberg; Karin Boman; Bengt Tholander; Giovanni Scambia; Nicholas Reed; Gennaro Cormio; Germana Tognon; Jackie Clarke; Tomasz Sawicki; Paolo Zola; Gunnar Kristensen Journal: Eur J Cancer Date: 2010-07-07 Impact factor: 9.162
Authors: M Bijoy Thomas; Andrea Mariani; William A Cliby; Gary L Keeney; Karl C Podratz; Sean C Dowdy Journal: Gynecol Oncol Date: 2007-09-06 Impact factor: 5.482
Authors: Cyriac Kandoth; Nikolaus Schultz; Andrew D Cherniack; Rehan Akbani; Yuexin Liu; Hui Shen; A Gordon Robertson; Itai Pashtan; Ronglai Shen; Christopher C Benz; Christina Yau; Peter W Laird; Li Ding; Wei Zhang; Gordon B Mills; Raju Kucherlapati; Elaine R Mardis; Douglas A Levine Journal: Nature Date: 2013-05-02 Impact factor: 49.962
Authors: N M de Lange; N P M Ezendam; J S Kwon; I Vandenput; D Mirchandani; F Amant; L J M van der Putten; J M A Pijnenborg Journal: Curr Oncol Date: 2019-04-01 Impact factor: 3.677
Authors: Benjamin B Albright; Karen A Monuszko; Samantha J Kaplan; Brittany A Davidson; Haley A Moss; Allan B Huang; Alexander Melamed; Jason D Wright; Laura J Havrilesky; Rebecca A Previs Journal: Am J Obstet Gynecol Date: 2021-05-04 Impact factor: 10.693
Authors: Claire J Tobias; Ling Chen; Alexander Melamed; Caryn St Clair; Fady Khoury-Collado; Ana I Tergas; June Y Hou; Chin Hur; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: JAMA Netw Open Date: 2020-12-01
Authors: Laura M Chambers; Danielle Chau; Meng Yao; Anthony B Costales; Peter G Rose; Chad M Michener; Robert Debernardo; Roberto Vargas Journal: Gynecol Oncol Rep Date: 2021-10-15
Authors: Allan B Huang; Jenny Wu; Ling Chen; Benjamin B Albright; Rebecca A Previs; Haley A Moss; Brittany A Davidson; Laura J Havrilesky; Alexander Melamed; Jason D Wright Journal: Gynecol Oncol Rep Date: 2021-11-06
Authors: Jason D Wright; Yongmei Huang; Alexander Melamed; Benjamin B Albright; Grace C Hillyer; Rebecca Previs; M S Dawn L Hershman Journal: Gynecol Oncol Date: 2021-06-20 Impact factor: 5.304